StreetInsider.com News Articles

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Mon, 01 Jun 2026 08:00:00 -0400

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL.

A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.

About

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Mon, 01 Jun 2026 08:00:00 -0400

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL.

A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.

About

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Mon, 01 Jun 2026 08:00:00 -0400

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL.

A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.

About

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Mon, 01 Jun 2026 08:00:00 -0400

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL.

A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.

About

Form 8-K GERON CORP For: May 20

Wed, 27 May 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260527/26557623.html

Form 8-K GERON CORP For: May 20

Wed, 27 May 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260527/26557623.html

Form 4 GERON CORP For: May 20 Filed by: Bir Dawn Carter

Tue, 26 May 2026 19:45:00 -0400
si-local-file:///var/storage/secattach/20260526/26551899.html

Form 4 GERON CORP For: May 20 Filed by: Bir Dawn Carter

Tue, 26 May 2026 19:45:00 -0400
si-local-file:///var/storage/secattach/20260526/26551899.html

Form 4 GERON CORP For: May 20 Filed by: McDonald John F

Tue, 26 May 2026 19:45:00 -0400
si-local-file:///var/storage/secattach/20260526/26551900.html

Form 4 GERON CORP For: May 20 Filed by: McDonald John F

Tue, 26 May 2026 19:45:00 -0400
si-local-file:///var/storage/secattach/20260526/26551900.html

Form 4 GERON CORP For: May 20 Filed by: Molineaux Susan

Tue, 26 May 2026 19:45:00 -0400
si-local-file:///var/storage/secattach/20260526/26551901.html

Form 4 GERON CORP For: May 20 Filed by: Molineaux Susan

Tue, 26 May 2026 19:45:00 -0400
si-local-file:///var/storage/secattach/20260526/26551901.html

Form 4 GERON CORP For: May 20 Filed by: O'Farrell Elizabeth G.

Tue, 26 May 2026 19:45:00 -0400
si-local-file:///var/storage/secattach/20260526/26551902.html

Form 4 GERON CORP For: May 20 Filed by: O'Farrell Elizabeth G.

Tue, 26 May 2026 19:45:00 -0400
si-local-file:///var/storage/secattach/20260526/26551902.html

Form 4 GERON CORP For: May 20 Filed by: Spiegel Robert J.

Tue, 26 May 2026 19:45:00 -0400
si-local-file:///var/storage/secattach/20260526/26551903.html

Form 4 GERON CORP For: May 20 Filed by: Spiegel Robert J.

Tue, 26 May 2026 19:45:00 -0400
si-local-file:///var/storage/secattach/20260526/26551903.html

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 18 May 2026 16:01:00 -0400

FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.29 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 18 May 2026 16:01:00 -0400

FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.29 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 18 May 2026 16:01:00 -0400

FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.29 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 18 May 2026 16:01:00 -0400

FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.29 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares

Form SCHEDULE 13G/A GERON CORP Filed by: Deep Track Capital, LP

Fri, 15 May 2026 08:41:00 -0400
si-local-file:///var/storage/secattach/20260515/26500224.html

Form SCHEDULE 13G/A GERON CORP Filed by: Deep Track Capital, LP

Fri, 15 May 2026 08:41:00 -0400
si-local-file:///var/storage/secattach/20260515/26500224.html

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Tue, 12 May 2026 09:31:00 -0400

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population

Additional presentations at EHA 2026 and ASCO 2026 include abstracts related to ongoing myelofibrosis and AML clinical programs

FOSTER CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the first real-world evidence study of RYTELO® (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Tue, 12 May 2026 09:31:00 -0400

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population

Additional presentations at EHA 2026 and ASCO 2026 include abstracts related to ongoing myelofibrosis and AML clinical programs

FOSTER CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the first real-world evidence study of RYTELO® (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Tue, 12 May 2026 09:31:00 -0400

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population

Additional presentations at EHA 2026 and ASCO 2026 include abstracts related to ongoing myelofibrosis and AML clinical programs

FOSTER CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the first real-world evidence study of RYTELO® (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European